Form 144 Filer Information

**FORM 144** 

144: Filer Information

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

#### Form 144

NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

Filer CIK	0001805916	
Filer CCC	XXXXXXXX	
Is this a LIVE or TEST Filing?		
Submission Contact Information		
Name		
Phone		
E-Mail Address		
144: Issuer Information		
Name of Issuer	Syros Pharmaceuticals	
SEC File Number	001-37813	
Address of Issuer	35 Cambridge Park Drive Cambridge MASSACHUSETTS 02140	
Phone	6177441340	
Name of Person for Whose Account the Securities are To Be Sold	Flagship Pioneering Fund VII, L.P.	
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.		
Relationship to Issuer	Affiliate	
144: Securities Information	on	
Title of the Class of Securities To Be Sold	Common	
Name and Address of the Broker	J.P. Morgan Securities LLC 390 Madison Avenue 6th Floor New York NY 10017	
Number of Shares or Other Units To Be Sold	1331624	
Aggregate Market Value	279641	
Number of Shares or Other Units Outstanding	26832457	
Approximate Date of Sale	12/27/2024	
Name the Securities Exchange	Nasdaq	

any part of the purchase price or other consideration therefor:

144: Securities To Be Sold		
Title of the Class	Common	
Date you Acquired	09/15/2022	
Nature of Acquisition Transaction	Private Investment in a Public Entity	
Name of Person from Whom Acquired	Issuer	
Is this a Gift?	Date Donor Acquired	
Amount of Securities Acquired	278727	
Date of Payment	12/23/2024	
Nature of Payment	Cashless Exercise of Warrant Shares	

If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

## 144: Securities To Be Sold

Title of the Class	Common
Date you Acquired	12/22/2023
Nature of Acquisition Transaction	Registered Direct Offering
Name of Person from Whom Acquired	Issuer
Is this a Gift?	Date Donor Acquired
Amount of Securities Acquired	1052897
Date of Payment	12/23/2024
Nature of Payment	Cashless Exercise of Warrant Shares

If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

# 144: Securities Sold During The Past 3 Months

Name and Address of Seller	Flagship Pioneering Fund VII 35 CambridgePark Drive Cambridge MA 02140
Title of Securities Sold	Common
Date of Sale	12/13/2024
Amount of Securities Sold	1000000
Gross Proceeds	203019

# 144: Remarks and Signature

Remarks	
Date of Notice	12/27/2024

## **ATTENTION:**

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature	/s/ J.P. Morgan Securities LLC as agent and attorney-in-fact for Flagship Pioneering Fund VII, L.P.

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)